New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.3m revenue, or US$3.0m). Market cap is less than US$100m (AU$68.3m market cap, or US$48.7m). New Risk • Dec 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (AU$89.4m market cap, or US$59.9m). New Risk • Sep 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (AU$44.2m market cap, or US$29.1m). Announcement • Sep 12
Prescient Therapeutics Limited, Annual General Meeting, Oct 14, 2025 Prescient Therapeutics Limited, Annual General Meeting, Oct 14, 2025. Location: at level 33, 477 collins street, melbourne vic 3000 Australia New Risk • Aug 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Revenue is less than US$5m (AU$4.6m revenue, or US$3.0m). Market cap is less than US$100m (AU$44.7m market cap, or US$29.0m). Announcement • Jul 31
Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.9785 million. Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.9785 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 74,462,500
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Transaction Features: Subsequent Direct Listing Announcement • Jul 03
Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7 million. Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 175,000,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024 New Risk • Jul 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.7m free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$2.0m). Market cap is less than US$100m (AU$40.2m market cap, or US$26.4m). Announcement • Apr 10
Prescient Therapeutics Limited Appoints Melanie Farris as Independent Non-Executive Director and Serve as Chair of the Audit and Risk Committee Prescient Therapeutics Limited announced the appointment of Melanie Farris to the Board as independent Non-Executive Director. Ms Farris brings extensive senior executive and board-level experience with prior appointments including Non-Executive Director and Company Secretary at Factor Therapeutics Limited; Non-Executive Director, Chief Financial Officer and Company Secretary at Invion Limited; and Chair of the Board of Directors of Synapse Australia Limited. Most recently with Telix Pharmaceuticals Limited, Melanie's positions included Senior Vice President Global Governance Risk and Compliance, Chief Governance and Risk Officer and Group Company Secretary where she had responsibility for governance, risk, internal audit and sustainability frameworks, operations and compliance. Prior to her career in life sciences, Melanie was COO of the UK's FourFour Promotions Limited and Development Executive for The Prince's Foundation. Ms Farris holds a Bachelor of Communication (Public Relations) and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors. Ms Farris will serve as Chair of the Audit and Risk Committee. Announcement • Mar 26
Prescient Therapeutics Limited Opens First Clinical Site for PTX-100 Phase 2a Study Prescient Therapeutics Limited announced that the first Site Initiation Visit (SIV) of its Phase 2a clinical study of PTX-100 has been completed. The Phase 2a clinical study will evaluate two dosage levels of PTX-100 on an open-label basis in approximately 40 patients with relapsed/refractory (r/r) Cutaneous T Cell Lymphoma (CTCL). The primary endpoint is efficacy and the secondary endpoints are several including safety. This marks a significant milestone in the progress of the Phase 2a study for PTX-100 for patients suffering CTCL. It is the first of multiple sites that will be initiated in Australia, the USA and Europe. Announcement • Mar 25
Prescient Therapeutics Limited Announces Change of Chief Medical Officer Prescient Therapeutics Limited announced the appointment of Dr. Marissa Lim as Chief Medical Officer (CMO), effective 24th March 2025. Dr. Lim will take over from current CMO, Dr. Terrence Chew, who has guided Prescient's clinical programs for the past 10 years. Dr. Lim brings over 20 years of experience in the pharmaceutical and biotechnology industries, with a strong background in clinical development and regulatory affairs. Dr. Lim will oversee the clinical development of Prescient's innovative pipeline, including its lead drug candidate PTX-100, which is currently beginning a Phase 2 study in Cutaneous T cell lymphoma (CTCL). Dr. Lim will also be responsible for advancing Prescient's next-generation cell therapy platforms, OmniCAR and CellPryme, which have the potential to transform CAR-T therapies. Dr. Lim previously held senior positions at Vifor Pharma, Ipsen and Telix, where she led the development and subsequent launch of several successful haematology and oncology therapies. She has also served as Clinical and Medical Advisor, as well as serving as the CMO to several biotechnology companies, providing expertise in clinical trial design, drug development, and regulatory strategy. Announcement • Mar 11
Prescient Therapeutics Limited Announces Board Changes, Effective 30 March 2025 Prescient Therapeutics Limited announced that Mr. Steven Engle has advised the Board that he will be retiring as Chair, and standing down from
the Board of Directors on 30 March 2025 after more than ten years in the role. The Board of Directors has elected current non-executive director Dr. James Campbell to succeed Mr. Engle as Chair. Dr. Campbell will assume the position on 30 March 2025. The Company is undertaking a search for a new non-executive director who can replace Dr. Campbell as Chair of the Audit and Risk Committee when he assumes the role of Board Chair on
30 March 2025. New Risk • Feb 22
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.7m free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$2.8m revenue, or US$1.8m). Market cap is less than US$100m (AU$37.0m market cap, or US$23.6m). Announcement • Oct 14
Prescient Therapeutics Limited, Annual General Meeting, Nov 14, 2024 Prescient Therapeutics Limited, Annual General Meeting, Nov 14, 2024. Announcement • Jan 18
Prescient Therapeutics Limited Ordinary Shares to Be Deleted from OTC Equity Prescient Therapeutics Limited Ordinary Shares (Australia) will be deleted from OTC Equity effective January 18, 2024, due to Inactive Security. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Scientific Advisory Board H. Prince was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Oct 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$2.4m revenue, or US$1.5m). Market cap is less than US$100m (AU$48.3m market cap, or US$30.6m). Announcement • Oct 13
Prescient Therapeutics Limited, Annual General Meeting, Nov 16, 2023 Prescient Therapeutics Limited, Annual General Meeting, Nov 16, 2023, at 12:00 E. Australia Standard Time. Agenda: To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and auditors for the year ended 30 June 2023; to consider the Adoption of Remuneration Report; to consider and Re-election of Dr Allen Ebens as a Director of the Company; to consider the Election of Dr Ellen Feigal as a Director of the Company; to consider the Ratification of Prior Issue of 1,415,000; and to consider the Approval of 10% Placement Facility. Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Member of Scientific Advisory Board Phil Darcy was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • May 17
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director Prescient Therapeutics Limited announced the appointment of Dr. Ellen Feigal to the Board as a US-based independent, Non- Executive Director, effective 15 May 2023. Dr. Feigal brings a depth of experience in the commercialisation, product development and regulatory strategies in cell therapies, hematology and oncology. Her career spans leadership roles in industry, academia and nonprofits. Dr. Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing productdevelopment and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Dr. Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc.; Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Dr Feigal serves as a Board member for Xencor Inc. a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure a clinical-stage biotechnology company developing new immunotherapies to treat cancer. Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncologyfellowship at the University of California, San Francisco. Announcement • Jun 08
Prescient Therapeutics Limited Unveils New Clinic-Ready CAR-T Enhancement Platform Prescient Therapeutics unveiled its high-performance cell therapy manufacturing enhancement technology, named CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell manufacturing process. These cells are less prone to exhaustion, enabling longer duration of cancer killing activity, and are capable of improved tumour trafficking and penetrance compared to the current generation of CAR-T cells. Resultantly, CellPryme-M CAR-T cells perform significantly better than conventional CAR-T cells in highly aggressive solid cancer models. CellPryme-M was developed by Prescient in collaboration with world leading cancer research institute, the Peter MacCallum Cancer Centre (Peter Mac), with Prescient retaining whole ownership of intellectual property. CellPryme-M is now ready for use in clinical studies. Prescient plans to use CellPryme-M to enhance the cells used in its breakthrough OmniCAR programs. Additionally, Prescient will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter into value-adding collaborations with external parties. Cell phenotype determines clinical anti-cancer responses Although T cells are often referred to collectively, they are an extremely diverse group of cells with different sub-types, each with different characteristics and roles in the body. CAR-T clinical trials have clearly established that patient outcomes are much better when the CAR-T cells have less differentiated phenotypes (namely more central memory T cells)1. Current CAR-T therapies are often rich in effector T cells, which are important for cytotoxicity, but are prone to rapid exhaustion and cell death. It is therefore highly desirable for CAR-T therapies to include more helper T cells (which synergise with effector T cells) and more "youthful" central memory T cells, which have greater proliferative capacity and persist for much longer, resulting in longer lasting tumour killing ability. CellPryme-M produces superior CAR-T cell phenotypes The cells produced from the CellPryme-M process have many favourable characteristics required from more effective cell therapies, including: 50% more central memory T cells, a highly clinically relevant sub-type; Double proportion of CD4+ helper T cells, for synergy with effector T cells; Significantly more chemokine receptors, important for tumour trafficking and tumour penetrance, especially important in solid tumours; and Greater genomic stability and DNA repair for enhanced self-renewal. Importantly, the superior cell phenotype of CellPryme-M cells does not come at the expense of effectiveness, with T cells retaining their potency with no increased safety risks due to higher cytokine release. CellPryme-M CAR-T cells nearly doubled tumour control compared to conventional CAR-T, and significantly improved survival (double that of control) in a mouse model of highly aggressive breast cancer that is largely resistant to conventional CAR-T. An additional and unexpected finding during the development of CellPryme-M was the rapid activation of genes pertaining to potent anti-viral pathways. With cell therapies now being explored for treating infectious diseases, being able to produce T cells with enhanced anti-viral activity may provide a distinct advantage in creating effective therapies against viruses. Announcement • May 10
Prescient Therapeutics Limited Expands PTX-200 AML Cohort Following Additional Complete Remission Prescient Therapeutics Limited announced that its Phase 1b clinical study of PTX-200 and cytarabine in patients with relapsed and refractory acute myeloid leukemia (AML) will expand the cohort at 45 mg/m2 PTX-200 following another complete remission and no dose limiting toxicities at this dose level. Three patients were treated at 45 mg/m2 PTX-200 together with cytarabine, with no dose limiting toxicities reported. One patient in the cohort achieved a CRi, meaning complete remission of disease, with neutrophils and/or platelets yet recover to normal levels. CR (complete remission) and CRi are typically ascribed the same predictive value of successful treatment outcome This latest patient brings the total of complete remissions on this study to four patients. Additionally, one patient in the prior cohort at 35mg/m2 PTX-200 has been determined to have had a partial response (reduction in cancer burden). Approximately 158,000 patients globally suffer from AML, a cancer of the bone marrow that prevents formation of normal blood cells. AML progresses quickly and has poor survival rates. After initial chemotherapy, most patients relapse, leading to an ongoing unmet medical need. Announcement • Apr 06
Prescient Therapeutics Limited Announces Opening of Enrolment in the Expansion Cohort of the Phase 1b Trial of PTX-100 to Treat T-Cell Lymphomas Prescient Therapeutics Limited announced the opening of enrolment in the expansion cohort of the Phase 1b trial of PTX-100 to treat T-cell lymphomas, a group of aggressive and rare blood cancers with significant unmet clinical need. The expansion cohort is an open-label, non-randomised study that will enrol eight to 12 patients with relapsed and refractory T-cell lymphoma. It will be led by world-renowned hematologist, Professor H. Miles Prince at Epworth Hospital in Melbourne, Australia. Excellent safety data and encouraging preliminary evidence of clinical efficacy in patients with T-cell lymphomas in the Phase 1b study prompted clinical investigators to recommend expanding the study and to focus on enrolling patients with peripheral T-cell lymphomas (PTCL). PTCL is a blood cancer with substantial unmet need for new therapies and represents an exciting clinical and commercial opportunity for PTX-100. Prescient plans to include several patients with cutaneous T-cell lymphoma (CTCL) as well. CTCL clinical samples will bolster insights on drug activity in T-cell lymphomas overall. Prescient reported that drug shipment has arrived in Australia to support the trials. As previously reported, there were unforeseen delays in manufacturing of additional PTX-100 due to worldwide supply chain and logistics challenges that impacted so many sectors, including drug manufacturers and their suppliers. This drug supply is sufficient for the dosing of the planned expansion cohort. Despite the delayed start, Prescient is still aiming to complete recruitment of the expansion cohort by the end of 2022. One PTCL patient from the Phase 1b escalation cohort has now undergone 37 cycles of therapy and continues to receive PTX-100. This patient had particularly aggressive disease that had failed five prior therapies, none of which were able to control the disease for more than a few months before the disease progressed further. When treated with PTX-100, this patient experienced a partial response (reduction in cancer burden), and this response has endured for 24 months so far. Another patient with cutaneous T cell lymphoma (CTCL) also had aggressive disease and had failed three prior treatments. This patient had a partial response on the study, with reduced cancerous lesions and symptomatic relief. The patient was on therapy for 12 months, receiving 19 cycles of therapy. In both cases, such patients with refractory T-cell lymphomas on standard treatments would typically be expected to have disease progression within 4 months. This highlights the encouraging nature of the responses to PTX-100. Peripheral T-Cell Lymphoma (PTCL) PTCL encompasses a group of uncommon and aggressive cancers resulting from a patient's T-cells becoming cancerous. T-cells are an important part of the immune system which help the body fight infection. In cases when some T-cells start to grow too quickly and out of control, they can accumulate in the body. There are several sub-types of PTCL, but usually present in a similar way. PTCL generally affects people aged 60 years and older, although it can occur at any time throughout adulthood. Current treatments for PTCL include combination chemotherapy regimens, localised radiotherapy, stem cell transplants and steroid therapy. PTX-100 PTX-100 is a first-in-class targeted therapy that blocks an important cancer growth enzyme called GGT-1. It was co-invented by Prescient's Scientific Founder, Professor Said Sebti, and is exclusively licensed by Prescient from Yale University. In the prior Phase 1b basket study, a total of 10 patients were enrolled - five with solid tumours (pancreatic and colorectal cancers) and five with haematological malignancies (multiple myeloma and T-cell lymphomas). Patients had received a median of three prior lines of therapy and up to five prior lines of therapy. PTX-100 was administered at doses ranging from 500 mg/m2 to 2,000 mg/m2. No serious adverse events related to PTX-100 were observed, and a clinical signal was seen in T-cell lymphomas. Announcement • Jul 06
Prescient Therapeutics Limited Announces Results from in Silico Immunogenicity Testing of OmniCAR's Key Binding Components, SpyTag and SpyCatcher Prescient Therapeutics Limited announced excellent results from in silico immunogenicity testing of OmniCAR's key binding components, SpyTag and SpyCatcher. These results substantially de-risk the entire platform and are important for progressing Prescient's in-house programs and external collaborations with OmniCAR. Immunogenicity testing evaluates the immune response against a new therapy, which can adversely affect safety and efficacy. In the case of CAR-T cell therapies, high levels of immunogenicity can adversely impact CAR-T cell expansion and persistence, which can impact the overall safety and clinical response of the treatment. The immunogenicity of OmniCAR's binding system components SpyTag and SpyCatcher were tested in silico by an independent US research provider to determine if either component has the potential to elicit unfavourable immune responses that could compromise the therapy. The results demonstrated that both SpyTag and SpyCatcher have very low immunogenicity - lower than a panel of humanised therapeutic antibodies already approved for human use and on par with circulating human antibodies. It is worth noting that in silico immunogenicity testing is widely recognised as being over-predictive as contemporary algorithms are unable to account for cellular antigen processing. The development follows the successful completion of manufacturing and delivery of critical components of the OmniCAR platform including cell binders for several cancer targets and lentiviral vectors used to produce CAR-T cells. Prescient is developing OmniCAR programs for acute myeloid leukemia; Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (the most common form of brain cancer). In addition, Prescient has developed OmniCAR as a platform, allowing collaborations and partnerships under licence with third parties wishing to incorporate OmniCAR to enhance their respective cell therapies. The OmniCAR platform is based on technologies developed at the University of Pennsylvania and University of Oxford. Prescient has a worldwide licence to commercialise the technologies. Announcement • Jun 25
Prescient Therapeutics Limited Completes Car-T Manufacturing Milestone for Omnicar Prescient Therapeutics Limited announced the successful completion of the manufacturing and delivery of crucial components of
the OmniCAR platform for Prescient's in-house programs of next-generation CAR-T therapies. A range of binders against a variety of cancer targets, including CLL-1; CD33; Her2 and EGFRviii, have been manufactured by a leading US antibody manufacturer. All binders have incorporated
SpyTag, which is required for covalent binding to immune cells (such as T-cells) in the OmniCAR system. A range of binders against a variety of cancer targets, including CLL-1; CD33; Her2 and EGFRviii, have been manufactured by a leading US antibody manufacturer. All binders have incorporated
SpyTag, which is required for covalent binding to immune cells (such as T-cells) in the OmniCAR system. The OmniCAR platform is based on technologies developed at the University of Pennsylvania and University of Oxford. Prescient has the worldwide license to commercialize the technologies. Announcement • Jan 19
Prescient Therapeutics Announces its Internal Development Programs for OmniCAR, a Next-Generation CAR-T Therapy Platform Prescient Therapeutics announced its internal development programs for OmniCAR, a next-generation CAR-T therapy platform. OmniCAR is a universal immune receptor technology platform that offers a number of potential benefits over existing CAR-T therapies, including control, safety, flexibility and efficacy. With a platform technology with such a broad range of potential applications, it was important for Prescient to strategically select indications and applications for internal development that struck a balance between market opportunity, technical complexity and product differentiation. The strategic review was led by Prescient and its Scientific Advisory Board. The review took into account all the known CAR-T programs in development worldwide and had input from leaders from multiple disciplines, including the inventors; clinicians; researchers; venture capitalists and healthcare investors; leading non-profit cancer organizations and antibody experts. Prescient announced three internal programs representing significant market opportunities, where current-generation CAR-T have faced challenges, but where the unique capabilities of OmniCAR may present distinct advantages. The development programs are: OmniCAR CD33 and CLL-1 for Acute Myeloid Leukemia (AML); OmniCAR Her2 for Her2+ solid tumours including breast, ovarian and gastric cancers; and OmniCAR Her2 and EGFRviii for glioblastoma multiforme (GBM). The application of OmniCAR technology in these cancers is expected to have benefits over conventional CAR T therapy, including: titration for improved safety; the ability to switch antigen targeting; co-arming CAR-T against multiple antigens simultaneously; persistent dosing and tumour microenvironment enhancements to improve efficacy. The vigorous development program will move OmniCAR towards clinical programs while demonstrating the unique features of the technology in treating patients, which will add tremendous value to the OmniCAR platform. Announcement • Dec 18
Prescient Therapeutics Limited Appoints H. Miles Prince AM to tis Scientific Advisory Board Prescient Therapeutics announced the appointment of internationally renowned Australian haematologist and blood cancer researcher Professor H. Miles Prince AM to its Scientific Advisory Board (SAB). Professor Prince has contributed to the successful development of several new cancer therapies now in use worldwide. He is lead investigator in the Phase 1b trial of Prescient's targeted anti-cancer therapy, PTX-100, currently enrolling patients at Melbourne's Epworth Healthcare and Peninsula & South Eastern Haematology and Oncology Group. In addition to advancing revolutionary new targeted therapies like PTX-100, Professor Prince has pioneered the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies in Australia. Announcement • Aug 26
Prescient Therapeutics Limited announced that it expects to receive AUD 7.046084 million in funding Prescient Therapeutics Limited (ASX:PTX) announced a private placement of 128,110,611 common shares at a price of AUD 0.055 per share for gross proceeds of AUD 7,046,083.605 on August 26, 2020. The transaction will include participation from existing and new professional and sophisticated investors. The transaction is expected to close on or around August 28, 2020, subject to receipt of funds on August 27, 2020. Announcement • Aug 19
Prescient Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Prescient Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 72,727,273
Price\Range: AUD 0.055
Discount Per Security: AUD 0.00385
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,454,545
Price\Range: AUD 0.055 
